These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 38708965

  • 1. Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus.
    Servais AM, McMullen JS, Bowen R, Kleiboeker SB, Ulloa I, Duncan K, Miles CD.
    Transpl Infect Dis; 2024 Aug; 26(4):e14291. PubMed ID: 38708965
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 3. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
    Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA.
    JAMA; 2023 Jul 03; 330(1):33-42. PubMed ID: 37279999
    [Abstract] [Full Text] [Related]

  • 4. Real-World Experience With CMV inSIGHT T Cell Immunity Testing in High-Risk Kidney and Pancreas Transplant Recipients.
    Descourouez JL, Smith JA, Saddler CM, Mandelbrot DA, Odorico JS, Jorgenson MR.
    Ann Pharmacother; 2024 Aug 03; 58(8):796-802. PubMed ID: 37897238
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
    Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK.
    Pharmacotherapy; 2004 Oct 03; 24(10):1323-30. PubMed ID: 15628830
    [Abstract] [Full Text] [Related]

  • 6. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
    Jorgenson MR, Kleiboeker H, Garg N, Parajuli S, Mandelbrot DA, Odorico JS, Saddler CM, Smith JA.
    Transpl Infect Dis; 2022 Feb 03; 24(1):e13766. PubMed ID: 34799964
    [Abstract] [Full Text] [Related]

  • 7. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K, Mitro G, Buschor K, Rees M, Ortiz J.
    Transpl Immunol; 2019 Oct 03; 56():101226. PubMed ID: 31344441
    [Abstract] [Full Text] [Related]

  • 8. Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis.
    Limaye AP, Green ML, Edmison BC, Stevens-Ayers T, Chatterton-Kirchmeier S, Geballe AP, Singh N, Boeckh M.
    J Infect Dis; 2019 Jul 31; 220(5):752-760. PubMed ID: 31112280
    [Abstract] [Full Text] [Related]

  • 9. Pre-transplant assessment of pp65-specific CD4 T cell responses identifies CMV-seropositive patients treated with rATG at risk of late onset infection.
    López-Oliva MO, Martínez V, Rodríguez-Sanz A, Álvarez L, Santana MJ, Selgas R, Jiménez C, Bellón T.
    Clin Immunol; 2020 Feb 31; 211():108329. PubMed ID: 31891764
    [Abstract] [Full Text] [Related]

  • 10. Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.
    La Rosa C, Limaye AP, Krishnan A, Blumstein G, Longmate J, Diamond DJ.
    Transpl Int; 2011 Sep 31; 24(9):920-31. PubMed ID: 21672050
    [Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.
    Transpl Infect Dis; 2012 Jun 31; 14(3):248-58. PubMed ID: 22385394
    [Abstract] [Full Text] [Related]

  • 12. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
    Witzke O, Nitschke M, Bartels M, Wolters H, Wolf G, Reinke P, Hauser IA, Alshuth U, Kliem V.
    Transplantation; 2018 May 31; 102(5):876-882. PubMed ID: 29166336
    [Abstract] [Full Text] [Related]

  • 13. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
    Herrera S, Khan B, Singer LG, Binnie M, Chaparro C, Chow CW, Martinu T, Tomlinson G, Keshavjee S, Husain S, Tikkanen JM.
    Transpl Infect Dis; 2020 Aug 31; 22(4):e13277. PubMed ID: 32170813
    [Abstract] [Full Text] [Related]

  • 14. Dynamics of cytomegalovirus-specific T-cell recovery in allogeneic hematopoietic cell transplant recipients using a commercially available flow cytometry assay: A pilot study.
    Jacobs SE, Ibrahim U, Vega AB, Lagdameo J, Callahan J, Govindarajulu U, Gitman M, Levine JE, Rana M, Keyzner A.
    Transpl Infect Dis; 2024 Jun 31; 26(3):e14290. PubMed ID: 38708941
    [Abstract] [Full Text] [Related]

  • 15. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.
    Santos CA, Brennan DC, Saeed MJ, Fraser VJ, Olsen MA.
    Clin Transplant; 2016 Apr 31; 30(4):435-44. PubMed ID: 26841129
    [Abstract] [Full Text] [Related]

  • 16. Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients.
    Imlay H, Dumitriu Carcoana AO, Fisher CE, Wong B, Rakita RM, Fishbein DP, Limaye AP.
    Transpl Infect Dis; 2020 Jun 31; 22(3):e13255. PubMed ID: 32020736
    [Abstract] [Full Text] [Related]

  • 17. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S, Li C, Cross RP, DePiero KA, Dick TB, Ferguson K, Kim M, Newkirk E, Park JM, Sudaria-Kerr J, Tichy EM, Ueda KR, Weng R, Wisniewski J, Gabardi S.
    Transpl Infect Dis; 2016 Dec 31; 18(6):904-912. PubMed ID: 27639246
    [Abstract] [Full Text] [Related]

  • 18. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
    Chiereghin A, Potena L, Borgese L, Gibertoni D, Squarzoni D, Turello G, Petrisli E, Piccirilli G, Gabrielli L, Grigioni F, Lazzarotto T.
    J Clin Microbiol; 2018 Apr 31; 56(4):. PubMed ID: 29305542
    [Abstract] [Full Text] [Related]

  • 19. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
    San-Juan R, Navarro D, García-Reyne A, Montejo M, Muñoz P, Carratala J, Len O, Fortun J, Muñoz-Cobo B, Gimenez E, Eworo A, Sabe N, Meije Y, Martín-Davila P, Andres A, Delgado J, Jimenez C, Amat P, Fernández-Ruiz M, López-Medrano F, Lumbreras C, Aguado JM, REIPI Network.
    Transpl Infect Dis; 2015 Oct 31; 17(5):637-46. PubMed ID: 26134282
    [Abstract] [Full Text] [Related]

  • 20. Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients.
    Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA.
    Drug Des Devel Ther; 2012 Oct 31; 6():289-95. PubMed ID: 23091373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.